Healthcare Global Enterprises Limited — PPTs, 01-08-2025: Investor Presentation

**1. Financial Highlights:**

HCG's Q1 FY26 revenue grew 17% YoY to **₹613.2 Cr**, with Adjusted EBITDA up 20% to **₹111.8 Cr** (18.2% margin). Profit After Tax (Post-IND AS) decreased to **₹4.7 Cr**, impacted by higher depreciation and finance costs from expansion. Operational beds expanded to 2,189. Net debt (incl. leases) rose to **₹1,569.7 Cr**.

**2. Strategic Initiatives & Growth Drivers:**

Growth is driven by a 'focused factory' approach and continuous tech investments (AI, genomics). The company prioritizes improving profitability at emerging centers and saw significant digital marketing revenue growth. Ongoing capex supports future expansion.

**3. Business Developments:**

HCG expands its pan-India presence with 22 cancer centers across 19 cities. Focus is on accelerating growth in established market-leading centers via enhanced clinical teams and marketing.

**4. Market Position & Competitive Advantage:**

As India's largest oncology chain, HCG holds leading positions in most cities. It leverages its extensive network, 'Tumor Board approach', and advanced technology for superior clinical outcomes and scale advantage.

**5. Investor Implications:**

Strong revenue and EBITDA growth signal positive potential. While PAT was affected by expansion costs, improving ROCE in emerging centers suggests future profitability. Debt management and capex execution are key areas for investor focus.